Taking the lead: Sangamo Therapeutics Inc (SGMO)

With 7.25 million shares changed hands, the volume of the stock remained heavier than its average volume of 6.66 million shares. The 52-week range on SGMO shows that it touched its highest point at $3.18 and its lowest point at $0.30 during that stretch. It currently has a 1-year price target of $5.00. Beta for the stock currently stands at 1.38.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SGMO was down-trending over the past week, with a drop of -15.15%, but this was down by -6.78% over a month. Three-month performance dropped to -50.65% while six-month performance fell -64.00%. The stock gained 17.24% in the past year, while it has lost -40.00% so far this year. A look at the trailing 12-month EPS for SGMO yields -0.52 with Next year EPS estimates of -0.35. For the next quarter, that number is -0.12. This implies an EPS growth rate of 44.04% for this year and -26.10% for next year.

Float and Shares Shorts:

At present, 224.71 million SGMO shares are outstanding with a float of 214.84 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SGMO since 3 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.41391 being high and -$0.55878 being low. For SGMO, this leads to a yearly average estimate of -$0.476.